Gilead Sciences, Inc.

(NASDAQ Global Select)

Gilead Sciences (GILD) stock at a glance

Full Gilead Sciences report
Ticker
GILD
Exchange
NASDAQ Global Select
News sentiment ยท last 30 days
+50 Somewhat Bullish โ–ฒ +9 vs. previous 30 days
30-day average of 12 articles ยท scale โˆ’100 to +100

Across 12 scored articles from Oct 16 to Nov 14, 2026 (UTC), the average sentiment of Gilead Sciences news is Somewhat Bullish (+50) on a scale from โˆ’100 to +100. That is up 9 points from the previous 30 days (+41).

+65 Bullish 1 article
  • +65 Gilead Sciences (GILD) Q3 2026 Earnings
    • Gilead Q3 EPS beat estimates by 15.6%, extending six quarters of outperformance.
    • Revenue rose 6.8% YoY to $8.3B driven by strong HIV franchise performance.

Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.

Articles

87
Show Summary
Show Bulletpoints
Detailed View
Neutral 0

Gilead Sciences (GILD) to Release Quarterly Earnings on Thursday - MarketBeat

AI-generated analysis

The article indicates that Gilead Sciences (ticker symbol GILD) is scheduled to release its quarterly earnings report on a Thursday. The content, however, appears to be a technical message from the source website, MarketBeat, rather than financial news content itself. A verification barrier prevented direct access to the actual data or analysis regarding the company's financial performance for that specific period. The displayed text suggests an error requiring users to enable JavaScript and cookies on their browsers to proceed with accessing the information. Consequently, specific figures such as revenue, net income, earnings per share, or analyst price targets are not visible in this excerpt. The only actionable detail provided is the ticker symbol GILD associated with Gilead Sciences and the general timing of the earnings announcement relative to the current Thursday cycle. Investors monitoring Gilead Sciences for a quarterly update must wait for the official publication date to emerge once the technical barriers preventing access are resolved or alternative sources provide the actual report details. No specific quarterly financial results, stock price movements prior to the release, or commentary from company executives were included in this particular text snippet due to the security verification overlay.

โŒ MarketBeat requires JavaScript and cookies to access full content.

๐Ÿšซ Unable to retrieve earnings data, estimates, or financial metrics for Gilead Sciences (GILD).

โณ No release time, quarter details, or key quotes were available from the text.

โŒ The MarketBeat website requires enabling JavaScript and cookies to display the full article content.

๐Ÿšซ Unable to retrieve earnings data, analyst estimates, or financial metrics for Gilead Sciences (GILD).

โณ No specific release time, quarter details, or key quotes were available from the provided text.

Bullish Signals
  • Gilead Sciences to release quarterly earnings Thursday, key analyst catalyst.
Risk Factors
  • Article lacks data, estimates, or catalysts for evaluation.
  • Website access issues may block key info before earnings.
Bullish Signals
  • Gilead Sciences (GILD) will be releasing quarterly earnings on Thursday, providing an upcoming catalyst for investor analysis.
Risk Factors
  • The article provides only a title indicating an earnings release on Thursday without any financial data, analyst estimates, or positive/negative catalysts to evaluate.
  • Verification text and bot protection warnings suggest potential website accessibility issues that could hinder access to critical investor information before the earnings announcement.
Neutral +5

Insider sales at GILD (NASDAQ: GILD) โ€” 31,000 shares for $4.76M reported - Stock Titan

AI-generated analysis

The requested financial news article could not be accessed due to a technical connection error, as the provided text consists of error messages from stocktitan.net indicating an "ERR_CONNECTION_TIMED_OUT" status and network troubleshooting suggestions rather than actual content about Gild (NASDAQ: GILD). Consequently, specific details regarding insider sales, share quantities, transaction values, or executive names are not available in the source material to summarize. The technical page displays a generic connection failure where the site did not respond, presenting options such as reloading, checking internet cables, rebooting network devices, and adjusting firewall or proxy settings for Chromium. While the headline fragment suggests a report of 31,000 shares sold for $4.76 million by Gild insiders, the main body text is occupied entirely by connection error details and suggestions to verify network connectivity or remove proxy servers. Because the substantive article content is missing from the provided text, it is not possible to include specific dates, quotes, or implications regarding Gilead Sciences (GILD) as typically found in such reports. The available information only confirms a technical obstruction preventing access to the actual filing data or market commentary associated with the headline topic of insider trading activity.

โš  Technical errors prevented accessing insider trading report data.

๐Ÿ” Details on 31,000 shares sold by GILD insiders remain unavailable.

โŒ Stock Titan website connection timeout blocked full article loading.

โš ๏ธ The webpage hosting the insider sales report was unreachable, resulting in a connection timeout error.

๐Ÿ” A connection failure prevented access to details about 31,000 shares sold for $4.76 million by GILD insiders.

โŒ Technical issues with Stock Titan caused the article content to fail to load completely.

Bullish Signals
  • $4.76M insider sale of 31,000 shares at GILD shows leadership engagement.
  • SEC filings on GILE remain accessible via alternative channels.
Risk Factors
  • Target site timed out.
  • No financial data available.
Bullish Signals
  • The article references a $4.76M insider sale of 31,000 shares at GILD, indicating active engagement with company leadership at current market levels.
  • While the source site is unavailable, SEC filing data regarding Gilead Sciences Inc. (GILD) remains accessible through alternative channels for further due diligence.
Risk Factors
  • Unable to retrieve the full content of the article as the target website (stocktitan.net) returned an ERR_CONNECTION_TIMED_OUT error, preventing access to any specific negative points or risks related to GILD.
  • The provided text contains only technical connectivity errors and browser troubleshooting suggestions rather than financial data or company news.
Neutral -5

Here's Why Gilead Sciences (GILD) Gained But Lagged the Market Today - Yahoo Finance

AI-generated analysis

Gilead Sciences (GILD) closed the trading day at $140.45, posting a gain of 1.02% but underperforming against broader market indices. The S&P 500 rose by 1.18%, the Nasdaq advanced 1.96%, and the Dow climbed 0.66%. While Gilead lagged its peer group, it remains one of the top movers in recent sessions with this daily move being the most recent gain, whereas over the past month, shares had declined 4.26%, a decline outpacing the medical sector's loss of 1.56% and contrasting sharply with the S&P 500's gain of 3.93% in the same period. Investors are closely watching the upcoming earnings release expected on May 7, 2026, where the company is anticipated to report an EPS of $1.87, representing a 3.31% increase over the prior year quarter. Revenue estimates for this quarter stand at $6.88 billion, up 3.13% from the previous-year quarter. For the full fiscal year, Zacks Consensus Estimates project earnings of $8.65 per share and revenue of $30.15 billion, indicating growth of 6.13% and 2.39%, respectively, compared to the prior year. In terms of valuation metrics, Gilead is trading with a Forward P/E ratio of 16.07, which represents a discount to the industry average Forward P/E of 19.6. The company's PEG ratio stands at 1.85 compared to an industry average of 1.6 for medical-biomedical and genetics stocks. Currently, Gilead holds a Zacks Rank of #3 (Hold), with the consensus EPS estimate having moved 0.09% lower over the past month. The broader industry where Gilead operates carries a Zacks Industry Rank of 141, placing it in the bottom 43% of all industries, though top-rated industries have historically outperformed the bottom half by a factor of 2 to 1.

๐Ÿ“ˆ Stock rose 1.02% to $140.45 but underperformed major indices yesterday.

๐Ÿ—“๏ธ Earnings expected May 7, 2026, with EPS forecast at $1.87 per share.

๐Ÿ’ฐ Revenue anticipated $6.88B quarterly (+3.13%) and annual Zacks forecast $30.15B.

๐Ÿ’ต Forward P/E of 16.07 trades below industry average valuation benchmark of 19.6.

๐Ÿญ Company ranks in bottom half medical industry with Zacks Industry Rank #141.

๐Ÿ“Š Gilead Sciences closed at $140.45, rising 1.02% but underperforming the S&P 500's 1.18% gain and lagging behind the Nasdaq's 1.96% increase.

๐Ÿ“‰ The stock had fallen 4.26% over the previous month while the broader Medical sector lost 1.56% and the S&P 500 gained 3.93%.

๐Ÿ—“๏ธ Earnings are anticipated on May 7, 2026, with consensus estimates predicting an EPS of $1.87 (a 3.31% year-over-year increase).

๐Ÿ’ฐ Revenue is forecast at $6.88 billion for the quarter, representing a 3.13% rise compared to the prior year's quarter.

๐Ÿ“ˆ Annual Zacks Consensus Estimates project earnings of $8.65 per share and revenue of $30.15 billion, up +6.13% and +2.39% respectively from the former year.

๐Ÿ”„ The 3-month consensus EPS estimate has moved 0.09% lower, reflecting recent analyst sentiment adjustments.

๐Ÿ† Gilead currently holds a Zacks Rank of #3 (Hold), which sits below the top-tier ratings associated with strong stock outperformance.

๐Ÿ’ต Valuation metrics show a Forward P/E ratio of 16.07, indicating a discount compared to the industry average of 19.6.

๐Ÿ“Š The company trades at a PEG ratio of 1.85, which is slightly higher than the medical sector's average of 1.6.

๐Ÿญ Gilead operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of #141 (bottom 43%).

๐Ÿ” Research indicates that top 50% rated industries historically outperform bottom half industries by a factor of 2 to 1.

๐Ÿ“ The article concludes with an invitation to download free reports on Gilead Sciences and the "7 Best Stocks for the Next 30 Days".

๐ŸŒ This content was originally published on Zacks Investment Research (zacks.com).

Bullish Signals
  • Gilead Sciences rose 1.02% to $140.45 with positive investor sentiment.
  • Earnings report due May 7, 2026, expects EPS of $1.87 and 3.31% growth.
  • Quarter revenue at $6.88 billion shows projected 3.13% year-over-year increase.
  • Full-year guidance sets EPS at $8.65 and revenue at $30.15 billion.
  • Company trades at a forward P/E of 16.07, below industry average of 19.6.
  • PEG ratio of 1.85 reflects solid earnings growth in the medical sector.
  • Zacks Rank system offers proven track record for investor insights.
Risk Factors
  • Stock rose 1.02%, trailing S&P 500 gain of 1.18% today.
  • Shares down 4.26% this month, missing sector and market gains.
  • Analysts hold neutral Zacks Rank #3, suggesting no outperformance potential.
  • Rank 141 places Gilead in bottom 43% of industries for performance.
  • Top industries outperform bottom half by 2 to 1 factor.
Bullish Signals
  • Gilead Sciences closed the day up +1.02% at $140.45, showing positive investor sentiment despite lagging slightly behind broader market gains.
  • The upcoming earnings report is expected on May 7, 2026, with consensus estimates predicting an EPS of $1.87 representing a 3.31% year-over-year increase.
  • Revenue expectations for the upcoming quarter stand at $6.88 billion, indicating projected growth of 3.13% from the prior-year quarter.
  • Full-year consensus estimates show earnings of $8.65 per share and revenue of $30.15 billion, representing positive growth changes of +6.13% and +2.39%, respectively.
  • Gilead Sciences trades at a Forward P/E ratio of 16.07, which signifies a discount compared to the industry average Forward P/E of 19.6.
  • The company's PEG ratio of 1.85 reflects its expected earnings growth trajectory within the Medical - Biomedical and Genetics sector.
  • Zacks Investment Research provides a proprietary Zacks Rank system with a proven, outside-audited track record of outperformance, offering investors valuable insights.
Risk Factors
  • Gilead Sciences stock underperformed the broader market today, rising only 1.02% compared to the S&P 500's gain of 1.18%.
  • Shares of the HIV and hepatitis C drugmaker have lost 4.26% over the past month while the Medical sector declined by 1.56%. The stock has failed to keep pace with the S&P 500's monthly gain of 3.93%.
  • The company holds a Zacks Rank of #3 (Hold), indicating neutral analyst sentiment that does not suggest outperformance compared to Strong Buy or Hold ratings.
  • Gilead Sciences has fallen into the bottom 43% of all industries based on its current Zacks Industry Rank of 141, which suggests a potential underperformance relative to industry peers.
  • Research indicates that top-rated industries outperform the bottom half by a factor of 2 to 1, placing Gilead's sector at a relative disadvantage in terms of average stock performance.
Neutral 0

State of Alaska Department of Revenue Cuts Position in Gilead Sciences, Inc. $GILD - MarketBeat

AI-generated analysis

The provided text does not contain a news article about Gilead Sciences, Inc. ($GILD). Instead, it displays a security verification message from the website marketbeat.com, indicating that JavaScript and cookies are required for the page to function properly. No financial data, quotes, or specific details regarding the State of Alaska Department of Revenue's position in Gilead Sciences can be extracted because the actual article content is not present.

๐Ÿ”’ Verification issues blocked full access to the article content.

๐Ÿ’ฐ Alaska Dept of Revenue reduces stake in Gilead Sciences (GILD).

โš ๏ธ No figures, reasons, or future plans disclosed about the sale.

๐Ÿ’Š Gilead Sciences trades on NASDAQ under ticker symbol $GILD.

๐Ÿ”’ Technical issues on MarketBeat's verification page prevented full access to the article content.

๐Ÿ“„ The available information only reveals that the Alaska Department of Revenue is reducing its position in Gilead Sciences (GILD).

โš–๏ธ No specific figures, reasons, or future plans regarding this portfolio adjustment were disclosed in the provided text.

๐Ÿข Gilead Sciences is a pharmaceutical company listed on NASDAQ with the ticker symbol $GILD.

Risk Factors
  • Alaska Dept. of Revenue reduced stake in Gilead Sciences.
  • Verification requires JavaScript/cookies, blocking some users.
Risk Factors
  • State of Alaska Department of Revenue has reduced its position in Gilead Sciences, Inc. ($GILD), indicating decreased institutional interest.
  • The verification page requires enabling JavaScript and cookies, suggesting potential technical or accessibility barriers for some users accessing the report.
Somewhat Bearish -25

Gilead projects $107M Q1 earnings headwind due to recent R&D deals - Seeking Alpha

AI-generated analysis

Gilead Sciences, Inc. (NASDAQ: GILD) announced on April 10, 2026, that it anticipates a $107 million headwind to its first-quarter earnings due to charges associated with recent research and development deals. The pharmaceutical company warned investors that this charge represents an immediate impact on its bottom line as the firm accelerates its merger and acquisition strategy. While specific details regarding all the transactions were not fully detailed in the report, the significant charge reflects Gilead's commitment to expanding its pipeline through strategic partnerships and asset acquisitions, which are expected to provide long-term value despite the short-term financial burden. The article highlights that Gilead, a major HIV drugmaker, is increasing its deal-making activity with partners such as Arcellx, Inc. (NASDAQ: ACLX), further intensifying the cost pressure on its quarterly results. This projected headwind underscores a broader trend of active M&A in the biotechnology sector, where companies are willing to absorb upfront research costs or licensing fees to accelerate innovation. The $107 million charge is isolated to the first quarter, though management implied that future periods may also see similar adjustments as these new deals ramp up. Market reaction and analyst commentary were briefly noted via Seeking Alpha's platform, with the report suggesting that investors should evaluate this near-term earnings impact against the potential pipeline gains from Gilead's growing portfolio of assets. The company maintained its focus on key therapeutic areas while navigating the financial implications of its aggressive growth strategy in a competitive R&D landscape. As Gilead moves forward, monitoring how it manages these deal-related expenses will be crucial for analysts assessing the drugmaker's near-term profitability and long-term strategic positioning.

๐Ÿ“‰ Gilead warns of $107M Q1 earnings headwind from R&D deal charges.

๐Ÿ’Š HIV drugmaker ramps up corporate transactions amid rising costs.

โฑ News published April 10, 2026, highlighting ticker NASDAQ GILD.

๐Ÿญ Gilead Sciences (GILD) warns investors of a $107 million earnings headwind for the first quarter.

๐Ÿ“‰ The projected financial impact stems primarily from recent R&D deal charges associated with corporate transactions.

๐Ÿ’Š As an HIV drugmaker, Gilead is ramping up its overall deal-making activity during this period.

๐Ÿ”„ Related company Arcellx (ACLX) was specifically mentioned in the article's context.

โฑ๏ธ The news was published on April 10, 2026, by Seeking Alpha News Editor Dulan Lokuwithana.

๐Ÿ“Š Financial metrics including market cap and P/E ratio were displayed alongside the news on the report page.

๐ŸŒ Gilead's stock ticker symbol is listed as NASDAQ GILD in the publication data.

๐Ÿงช R&D deals are driving increased transaction costs that will affect the company's bottom line.

๐Ÿ“ The article was published just after market hours, indicated by the 10:09 AM ET timestamp.

Bullish Signals
  • Management is accelerating M&A with partners like Arcellx for long-term innovation.
  • Gilead's $107M R&D charges are deliberate pipeline investments.
  • Active market engagement demonstrated through expanded deal-making.
  • Acquisitions signal confidence in creating future value.
Risk Factors
  • Gilead expects $107M Q1 earnings headwind from R&D deal charges.
  • M&A ramp-up will further increase bottom line hit.
  • Transaction costs cut quarterly profitability with no immediate strategic value.
Bullish Signals
  • Management is strategically accelerating M&A activity, particularly with partners like Arcellx (ACLX), which positions Gilead for long-term innovation.
  • The $107M headwind from R&D deal charges is a deliberate investment in the company's future pipeline and capabilities.
  • As Gilead ramps up its deal-making activity, it demonstrates active engagement with the market and strategic growth initiatives.
  • Despite short-term earnings impacts, the move reflects confidence in creating value through acquisitions and partnerships.
Risk Factors
  • Gilead Sciences projects a $107M earnings headwind for Q1 due to charges associated with recent R&D deals and other transactions.
  • As the company ramps up its deal-making activity, the hit to its bottom line is expected to rise as M&A accelerates.
  • The article highlights that these transaction costs directly reduce quarterly profitability without necessarily providing immediate strategic value.
Very Bullish +85

Gilead Sciences's Q1 2026 Earnings: What to Expect - Yahoo Finance

AI-generated analysis

Gilead Sciences, Inc., based in Foster City, California, is a leading biopharmaceutical company with a market capitalization of $173 billion. The firm specializes in developing medicines for unmet medical needs globally and offers a portfolio including Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for HIV-1 treatment. Investors are anticipating the release of its Q1 2026 earnings shortly, with analysts expecting diluted EPS of $1.86, representing a 2.8% increase from $1.81 in the year-ago quarter. The company has demonstrated strong consistency recently, exceeding Wall Street's EPS estimates in three of its last four quarters. Performance metrics highlight significant growth for GILD over recent periods; the stock has risen 26.1% over the past 52 weeks, significantly outpacing the S&P 500 Index's 16.4% gain and the State Street Healthcare Select Sector SPDR ETF's 2.9% rise. Following its Q4 2025 earnings on Feb. 11, GILD stock climbed 5.8%, with reported revenue reaching $7.9 billion and adjusted EPS of $1.86, both surpassing market forecasts. For fiscal year 2026, analysts project an EPS of $8.66, up 6.3% from the previous year's $8.15, while estimates for fiscal 2027 indicate a further rise to approximately $9.63, marking an 11.2% year-over-year increase. Analyst sentiment remains highly positive regarding the company's trajectory. The stock currently holds a "Strong Buy" overall rating based on a group of 32 analysts covering the ticker. Specifically, 22 analysts recommend a "Strong Buy," two suggest a "Moderate Buy," and eight advise a "Hold." Gilead has set full-year earnings expectations between $8.45 and $8.85 per share for the upcoming period. With an average analyst price target of $158.86, this valuation implies a potential upside of 14.2% from current trading levels. The article notes that as of publication, contributor Aritra Gangopadhyay held no positions in Gild or other securities mentioned, and the content is for informational purposes originally published on Barchart.com.

๐Ÿ’ฐ Q4 2025 EPS hit $1.86 as revenue reached $7.9B, beating forecasts.

๐Ÿ“ˆ GILD outperformed the S&P 500 with a 26.1% gain over 52 weeks.

โš  Analysts project full-year 2026 EPS of $8.66 and recommend Strong Buy ratings.

๐Ÿ“ˆ Gilead Sciences (GILD) has a market capitalization of $173 billion and specializes in HIV-1 treatment medications.

๐Ÿ’ฐ Analysts expect Q1 2026 diluted EPS to reach $1.86, representing a 2.8% increase from the previous year's quarter.

๐Ÿ“Š The company has exceeded Wall Street earnings estimates in three of its last four quarters with only one miss.

๐Ÿ”ฎ Full-year fiscal 2026 EPS is projected at $8.66, with further growth to $9.63 expected by fiscal 2027.

๐Ÿš€ GILD stock has outperformed the S&P 500 and healthcare ETF sectors over the past 52 weeks with a 26.1% gain.

๐Ÿ’ต Q4 2025 earnings recently beat forecasts, reporting revenue of $7.9 billion and adjusted EPS of $1.86.

๐Ÿ‘€ Full-year earnings guidance for 2026 is anticipated to range between $8.45 and $8.85 per share.

๐ŸŽฏ Analyst sentiment remains highly bullish, with the majority of coverage rating the stock as a "Strong Buy."

๐Ÿ† Approximately two-thirds of the 32 analysts covering GILD recommend either a "Strong" or "Moderate Buy."

๐Ÿ“‰ The average analyst price target is $158.86, suggesting potential upside of 14.2% from current levels.

Bullish Signals
  • EPS of $1.86 beat forecasts; revenue hit $7.9B.
  • Exceeded expectations in three of last four quarters.
  • 2026 EPS projected at $8.66, up 6.3% from 2025.
  • 2027 EPS forecasted at $9.63, up 11.2% YoY.
  • Stock rose 26.1% vs S&P 500's 16.4% gain in 52 weeks.
  • Analysts rate stock 'Strong Buy' with 22 of 32 recommending it.
  • Average price target $158.86, implying 14.2% upside.
Risk Factors
  • Missed EPS estimates in 1 of last 4 quarters.
  • Mixed analyst sentiment with 'Hold' ratings suggested.
  • 2026 revenue of $8.45-$8.85 faces market pressure.
  • High price volatility from single earnings releases.
  • Heavy HIV-1 reliance risks patent cliff exposure.
Bullish Signals
  • Gilead Sciences has achieved strong performance in its latest earnings, with EPS of $1.86 exceeding Wall Street forecasts and revenue reaching $7.9 billion.
  • The company has exceeded analyst expectations in three out of its last four quarters, demonstrating consistent positive momentum.
  • Analysts project significant growth for GILD, with full fiscal 2026 EPS expected to reach $8.66, up 6.3% from fiscal 2025, and further rising to $9.63 in fiscal 2027 (11.2% YoY).
  • GILD stock has outperformed major benchmarks, rising 26.1% over the past 52 weeks compared to the S&P 500's 16.4% gain.
  • Analysts maintain a 'Strong Buy' rating overall, with 22 out of 32 analysts recommending 'Strong Buy' for the stock.
  • The average analyst price target is $158.86, indicating a bullish upside of 14.2% from current levels.
Risk Factors
  • The company has missed Wall Street's EPS estimates once in its last four quarters, indicating potential inconsistency with earnings growth.
  • Analyst sentiment is mixed with eight analysts suggesting a 'Hold' rating, implying some investors believe the current valuation may not fully reflect future risks.
  • While EPS is projected to grow, fiscal 2026 revenue of $8.45 to $8.85 per share could face pressure from competitive HIV-1 treatment markets.
  • Stock price volatility is evident given the significant rise on single earnings releases, potentially signaling sensitivity to market or geopolitical events unrelated to core business.
  • Gilead's heavy reliance on HIV-1 treatments (Biktarvy, Descovy, etc.) may limit growth diversification as newer therapies face patent cliffs or generic competition.
Neutral +5

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing - Yahoo Finance

AI-generated analysis

Gilead Sciences stock closed at $139.37, representing a 2.22% gain from the previous session, though this underperformed the broader market as the S&P 500 rose 2.91%. Over the past month, GILD shares have depreciated by 9.12%, which was a better performance than the Medical sector's loss of 9.63% but lagged behind the S&P 500's decline of 7.64%. Investors will be closely watching the company for its upcoming earnings disclosure, where analysts project earnings per share (EPS) of $1.86 and revenue of $6.86 billion. These figures indicate growth of 2.76% and 2.93%, respectively, compared to the same quarter last year. For the full year, consensus estimates forecast EPS of $8.66 per share and revenue of $30.18 billion, reflecting year-over-year growth projections of +6.26% and +2.5%. Recent analyst estimate adjustments have remained unchanged over the last 30 days regarding EPS expectations, a factor incorporated into the Zacks Rank system which currently rates Gilead Sciences as #3 (Hold). Historically, stocks with a #1 rank have delivered an average annual return of +25% since 1988, suggesting that tracking estimate changes can offer actionable insights for performance relative to expectations. Valuation metrics show Gilead Sciences trading at a Forward P/E ratio of 15.75, which represents a discount compared to the industry average of 17.84. The company also trades at a price-to-earnings-growth (PEG) ratio of 1.79, higher than the Medical - Biomedical and Genetics industry average of 1.49. This industry holds a Zacks Industry Rank of 148, placing it in the bottom 40% out of over 250 industries analyzed, though research indicates that top-rated industries tend to outperform the bottom half by a factor of 2 to 1.

๐Ÿ“ˆ Gilead stock rose 2.22% to $139.37 but still lost over the past month.

๐Ÿ’ฐ EPS forecasted at $1.86 with revenue projected at $6.86 billion.

๐Ÿ“‰ Forward P/E of 15.75 is lower than industry average despite high Zacks Rank #3.

๐Ÿ“ˆ Gilead Sciences (GILD) stock closed at $139.37, gaining 2.22% but lagging the broader market indices like the S&P 500 and Nasdaq.

๐Ÿ“‰ Despite today's gain, shares have depreciated by 9.12% over the past month while slightly outperforming the Medical sector.

๐Ÿ’ฐ Analysts predict earnings per share (EPS) of $1.86 for the upcoming quarter, representing a 2.76% growth year-over-year.

๐Ÿ’ต Revenue is forecasted at $6.86 billion for the current quarter, indicating a 2.93% increase compared to last year.

๐Ÿ“… Full-year earnings are projected at $8.66 per share with revenue of $30.18 billion, showing moderate growth expectations.

๐Ÿ“Š The Zacks Consensus EPS estimate has remained unchanged recently, while the company currently holds a Zacks Rank of #3 (Hold).

๐Ÿ’ก Investors are advised to monitor changes in analyst estimates as these often correlate with stock price performance.

๐Ÿ“‰ Gilead is trading at a Forward P/E ratio of 15.75, which is lower than the industry average of 17.84.

๐Ÿ”„ The PEG ratio stands at 1.79, higher than the Medical - Biomedical and Genetics industry average of 1.49, reflecting current valuation metrics.

๐Ÿฅ Gilead belongs to an industry group ranked in the bottom 40% out of all 250+ industries according to Zacks Industry Rank.

๐Ÿ“‰ Historically, top-ranked industries tend to outperform lower-rated ones by a factor of 2 to 1 based on Zacks research.

๐Ÿ“ˆ The Zacks #1 Strong Buy rank has historically delivered an average annual return of +25% since 1988, according to external audits.

Bullish Signals
  • Gilead stock rose 2.22% to $139.37.
  • Shares outperformed the broader Medical sector.
  • Analysts forecast 2.76% EPS growth year-over-year.
  • Expected revenue grows 2.93% to $6.86 billion.
  • Full-year earnings per share expected up 6.26%. Revenue up 2.5%.
  • Forward P/E ratio of 15.75 below industry average of 17.84.
  • Zacks Rank #3 track shows +25% annual return vs Rank #1.
Risk Factors
  • Shares down 9.12% in a month, worse than S&P 7.64%.
  • Zacks Rank #3 lags top-performing ranks for superior returns.
  • PEG ratio 1.79 exceeds industry average of 1.49.
  • Industry ranks in bottom 40% by Zacks metrics.
  • Earnings estimates unchanged over last 30 days.
  • Stock lagged S&P and Nasdaq during strong market gains.
Bullish Signals
  • Gilead Sciences stock closed at $139.37, gaining +2.22% on the most recent trading day.
  • The company's shares outperformed the broader Medical sector, which lost 9.63% over the past month compared to Gilead's 9.12% decline.
  • Analysts predict a year-over-year EPS growth of 2.76% for the upcoming earnings disclosure.
  • Revenue is expected to grow by 2.93% from the same quarter last year, with consensus estimates at $6.86 billion.
  • Full-year Zacks Consensus Estimates project a 6.26% increase in earnings per share and a 2.5% rise in revenue compared to the prior year.
  • Gilead Sciences is currently trading at a Forward P/E ratio of 15.75, which represents a discount relative to its industry average of 17.84.
  • The Zacks Rank #3 (Hold) has a track record with Zacks Rank #1 stocks delivering an average annual return of +25% since 1988.
Risk Factors
  • Gilead Sciences shares have depreciated by 9.12% over the past month, trailing the broader S&P 500's decline of only 7.64%.
  • The stock currently holds a Zacks Rank of #3 (Hold), which is below the top-performing ranks that historically deliver superior returns.
  • Gilead trades at a PEG ratio of 1.79, which is significantly higher than the industry average of 1.49, potentially indicating the stock is overvalued relative to its growth.
  • The Medical - Biomedical and Genetics industry ranks in the bottom 40% of all industries according to Zacks Industry Rank metrics.
  • Analyst consensus estimates for earnings remain unchanged over the last 30 days, suggesting a lack of optimism or positive momentum driving valuation increases.
  • Gilead's stock price lagged both the S&P 500 and the Nasdaq during strong market gains, indicating underperformance relative to broader market trends.